


In re the application of:



TECH CENTER 1600/2900

RECEIVED-

P. BERCHTOLD et al.

Group Art Unit: 1632

Serial Number: 09/424,840

Examiner: Q. Li

Filed: December 3, 1999

Attorney Dkt. No.: 100564-09049

For: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES

STATEMENT UNDER 37 C.F.R. §1.821(c)

Commissioner for Patents Washington, D.C. 20231

Date: June 13, 2001

Sir:

In accordance with 37 C.F.R. §1.821(c), Applicants submit herewith the Sequence Listing for the above-identified application both in paper copy form and in computer readable form.

The names of the file on the computer readable form is 05649049.APP. The paper copy and the computer readable form are the same.

In the event that this paper is not considered to be timely filed, Applicants hereby petition for an appropriate extension of time. The fee for any such extension, or any other fee which may be required with respect to this paper, may be charged our Deposit Account No. 01-2300.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

aurence J. Edson Attorney for Applicants Registration No. 44,666

1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

LJE:kga

Enclosure: Sequence Listing

#28634-1

Notice to Comply

Application No.

09/424,840

Examiner

Applicant(s)

"JUN 1 9 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATED NOTICE CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

DISCLOSURES	
Applicant must file the items indicated below within the time penod s is attached to avoid abandonment under 35 U.S.C. § 133 (extension provisions of 37 CFR 1.136(a))	is of time may be obtained and of
The nucleotide and/or amino acid sequence disclosure contained in the requirements for such a disclosure as set forth in 37 C.F.R. 1.82	21 - 1.020 for the femousing(
1. This application clearly fails to comply with the requirements attention is directed to the final rulemaking notice published at 5 OG 29 (May 15, 1990). If the effective filing date is on or after notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 8	July 1, 1998, see the final rulemaking 32 (June 23, 1998).
 2. This application does not contain, as a separate part of the d Listing" as required by 37 C.F.R. 1.821(c). 	isclosure on paper copy, a "Sequence
3. A copy of the "Sequence Listing" in computer readable form 37 C.F.R. 1.821(e).	has not been submitted as required by
4. A copy of the "Sequence Listing" in computer readable form content of the computer readable form does not comply with the 1.823, as indicated on the attached copy of the marked -up "Ra	aw Sequence Listing."
5. The computer readable form that has been filed with this ap and/or unreadable as indicated on the attached CRF Diskette F readable form must be submitted as required by 37 C.F.R. 1.82	TODIETH IVEBOIL IV Capatitate agent
6. The paper copy of the "Sequence Listing" is not the same as "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
☑ 7. Other: Sequences listed in tables 3, 6, 7a, 7b are required labelled with SEQ ID Numbers.	d to comply with Sequence Rules and be
Applicant Must Provide:	
Applicant indist riovide. An initial or substitute computer readable form (CRF) copy of t	he "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as into the specification.	
	eadable copies are the same and, where (1(e) or 1.821(f) or 1.821(g) or 1.825(b) or
For questions regarding compliance to these requirement	ents, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support Technical Assistance	s-287-0200

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY